OncoMatch/Clinical Trials/NCT07255404
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Is NCT07255404 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Pumitamig and Nab-paclitaxel for pancreatic ductal adenocarcinoma (pdac).
Treatment: Pumitamig · Nab-paclitaxel · Gemcitabine · mFOLFIRINOX — This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (also known as BNT327, BMS-986545, or PM8002) in combination with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: systemic anticancer therapy for unresectable metastatic PDAC
Exception: adjuvant, neo-adjuvant, and peri-operative therapy allowed if completed >6 months prior to first dose
Have not received prior systemic therapy for unresectable metastatic PDAC. For participants who have received prior induction chemotherapy, concurrent chemoradiotherapy, or adjuvant/neoadjuvant chemotherapy for curative-intent, the interval should be at least 6 months from the end of the last treatment to relapse.
Cannot have received: PD-1/PD-L1/VEGF bispecific antibody
PD(L)-1/VEGF bispecific antibody, including monotherapy with either category or combinations thereof.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07255404 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy for unresectable metastatic PDAC, PD-1/PD-L1/VEGF bispecific antibody disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages